MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
18.98
-0.21 (-1.09%)
At close: Jun 16, 2026, 4:00 PM EDT
19.01
+0.03 (0.16%)
After-hours: Jun 16, 2026, 6:23 PM EDT
MoonLake Immunotherapeutics Employees
MoonLake Immunotherapeutics had 130 employees as of December 31, 2025. The number of employees increased by 30 or 30.00% compared to the previous year.
Employees
130
Change (1Y)
30
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,977,546
Market Cap
1.40B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 30 | 30.00% |
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| UroGen Pharma | 298 |
| Maze Therapeutics | 141 |
| Inhibrx Biosciences | 110 |
| Bicara Therapeutics | 103 |
| AtaiBeckley | 99 |
| ArriVent BioPharma | 77 |
MLTX News
- 5 weeks ago - MoonLake Immunotherapeutics Earnings release: Q1 2026 - Filings
- 5 weeks ago - MoonLake Immunotherapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - MoonLake price target raised to $45 from $40 at H.C. Wainwright - TheFly
- 5 weeks ago - MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street - TheFly
- 5 weeks ago - MoonLake says aligned with FDA on submission plans for sonelokimab - TheFly
- 5 weeks ago - MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year - TheFly
- 5 weeks ago - MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - MoonLake Immunotherapeutics Proxy statement: Proxy filing - Filings